Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain MYOK message board posts where the ticker symbol MYOK has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest MYOK SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-17-028252 Size: 7 KB
2017-12-08
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-17-028251 Size: 15 KB
2017-12-08
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-17-025636 Size: 11 KB
2017-11-08
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-17-025396 Size: 4 KB
2017-11-03
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-17-025395 Size: 4 KB
2017-11-03
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-17-025394 Size: 5 KB
2017-11-03
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001564590-17-021484 (34 Act)  Size: 4 MB
2017-11-03 001-37609
171176056
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001564590-17-021207 (34 Act)  Size: 284 KB
2017-11-02 001-37609
171172515
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-17-023789 Size: 9 KB
2017-10-06
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-17-023510 Size: 7 KB
2017-10-04
More MYOK SEC Filings


Related news from
Mon, 11 Dec 2017
12:25:08 +0000
MyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : December 11, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for MyoKardia, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more <b>(Read more...)</b>
Wed, 15 Nov 2017
13:00:00 +0000
Preclinical Studies with MyoKardia’s Mavacamten Demonstrate Evidence of Reduced Contractility and Improved Left Ventricular Compliance
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2017-- MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, ...
Tue, 14 Nov 2017
00:15:00 +0000
MyoKardia Presents Data from Study of Machine Learning Algorithm Intended to Identify Obstructive Hypertrophic Cardiomyopathy Using a Wearable Biosensor
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2017-- MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, ...
Wed, 08 Nov 2017
14:44:42 +0000
MyoKardia, Inc. – Value Analysis (NASDAQ:MYOK) : November 8, 2017
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives MyoKardia, Inc. a score of 71. Our analysis is based on comparing MyoKardia, Inc. with the following peers – OrganiGram Holdings Inc, Ohr Pharmaceutical, Inc., Oragenics, Inc. and OncoCyte Corp. (OGI-CA, OHRP-US, OGEN-US and OCX-US). Investment Outlook MyoKardia, Inc. has a fundamental score of 71 and has ... Read more <b>(Read more...)</b>
Tue, 07 Nov 2017
17:48:58 +0000
Myokardia Inc (MYOK) Q3:17 Update At First Glance
Shares of Myokardia Inc (NASDAQ:MYOK) are down nearly 3% Tuesday as investors digest the biotech firm's third-quarter financial results. The company reported Q3 EPS of $(0.42) in line with street consensus, and reflecting a total net loss for the quarter of $14.2 million. MyoKardia also provided an update on the company’s End-of-Phase 2 meeting with the FDA Division of Cardiovascular and Renal Products.  The meeting focused on MyoKardia’s proposed registration program for mavacamten (formerly MYK-461) in symptomatic, obstructive hypertrophic cardiomyopathy (oHCM).  MyoKardia is incorporating guidance from the FDA on study design elements and plans to proceed with the pivotal Phase 3 trial, EXPLORER-HCM, and a long-term extension study, as the key remaining studies in the mavacamten registration program.  The company anticipates dosing the first patient in EXPLORER-HCM in the second quarter of 2018.  Between now and study start, the company plans to review the final trial design with the FDA.
Tue, 07 Nov 2017
15:26:09 +0000
Edited Transcript of MYOK earnings conference call or presentation 2-Nov-17 8:30pm GMT
Q3 2017 MyoKardia Inc Earnings Call
Mon, 06 Nov 2017
12:17:33 +0000
MyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : November 6, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for MyoKardia, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more <b>(Read more...)</b>
Thu, 02 Nov 2017
21:54:17 +0000
MyoKardia reports 3Q loss
On a per-share basis, the South San Francisco, California-based company said it had a loss of 42 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed ...
Thu, 02 Nov 2017
20:02:00 +0000
MyoKardia Reports Third Quarter 2017 Financial Results and Operational Progress
Received FDA Feedback for Mavacamten Registration Program in Symptomatic, Obstructive Hypertrophic Cardiomyopathy. MyoKardia to Initiate EXPLORER-HCM as Pivotal Trial in Second Quarter 2018. Company to ...
Wed, 01 Nov 2017
12:00:00 +0000
MyoKardia Announces Presentations at 2017 American Heart Association Scientific Sessions
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2017-- MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, ...
Tue, 31 Oct 2017
12:00:00 +0000
MyoKardia to Present at Two Upcoming Investor Conferences in November
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2017-- MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, ...
Thu, 12 Oct 2017
12:24:58 +0000
MyoKardia, Inc. breached its 50 day moving average in a Bearish Manner : MYOK-US : October 12, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for MyoKardia, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more <b>(Read more...)</b>
Tue, 10 Oct 2017
15:39:03 +0000
ETFs with exposure to MyoKardia, Inc. : October 10, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to MyoKardia, Inc. Here are 5 ETFs with the largest exposure to MYOK-US. Comparing the performance and risk of MyoKardia, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more <b>(Read more...)</b>
Mon, 09 Oct 2017
13:51:25 +0000
MyoKardia, Inc. :MYOK-US: Earnings Analysis: Q2, 2017 By the Numbers : October 9, 2017
Categories: Yahoo FinanceGet free summary analysis MyoKardia, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 5.63 million, Net Earnings of USD -12.84 million. Change in operating cash flow of -19.98% compared to same period last year is about the same as change in earnings, likely no significant movement ... Read more <b>(Read more...)</b>
Mon, 02 Oct 2017
14:50:02 +0000
Best Sector ETF of Q3 and its Top-Performing Stocks
Inside the top performing stocks of top U.S.-focused ETF of Q3.
Wed, 27 Sep 2017
11:30:00 +0000
MyoKardia Provides Update on MYK-491 Clinical Progress
Single Ascending Dose Trial in Healthy Volunteers Continues Enrollment in Order to Refine Exposure-Activity-Relationship; Topline Data Expected by Early 2018. Next Trial of MYK-491 in DCM Patients Expected ...
Mon, 25 Sep 2017
23:01:00 +0000
Cramer's lightning round: Why I can't go down the path of...
Jim Cramer rattles off his take on callers' favorite stocks at lightning speed, including one struggling steel producer.
Mon, 18 Sep 2017
20:45:00 +0000
MyoKardia Unveils More Phase 2 Data on Heart Disease Treatment
The South San Francisco, Calif. on Sept. 18 presented additional data from the first patient cohort of its Phase 2 study
Mon, 18 Sep 2017
16:45:00 +0000
MyoKardia Presents Additional Positive Data from Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) at the Heart Failure Society of America’s 21st Annual Scientific Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2017-- MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, ...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "This is a site for sharing information about the atypical investments that the majority of investors have not discovered. It is about finding the next value/growth sector/investment before all the major houses on the Street are recommending it." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2017, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards